Cladribine, Cytarabine, And Etoposide (CCE)-Based Regimens Are Safe and Tolerable In Relapsed And Refractory AML Patients

Acta Haematol. 2023 Sep 14. doi: 10.1159/000534024. Online ahead of print.ABSTRACTIntensive treatment regimens for relapsed/refractory (R/R) acute myeloid leukemia (AML) generally include an anthracycline, cytarabine, with or without a purine analogue. In patients who cannot tolerate an anthracycline due to comorbidities may consider using etoposide. Given the ongoing fludarabine shortage, it has prompted the switch to other purine analogues, such as cladribine, in combination with cytarabine and etoposide in patients who may be eligible for intensive chemotherapy but not able to tolerate an anthracycline due to comorbidities or cardiotoxicity risks. Here we present four patients who received a CCE (cladribine, cytarabine, and etoposide) based regimen for R/R AML. There were no significant therapy-related adverse events, dose holds or delays. Two out of three evaluable patients were successfully bridged to allogeneic transplant, and one is pending another cycle of chemotherapy as a bridge to transplant. The CCE regimen offers a potential option for patients with R/R AML in need of an anthracycline free salvage regimen during a fludarabine shortage.PMID:37708871 | DOI:10.1159/000534024
Source: Acta Haematologica - Category: Hematology Authors: Source Type: research